217 related articles for article (PubMed ID: 25902869)
21. p21-activated kinase 1: PAK'ed with potential.
Ong CC; Jubb AM; Zhou W; Haverty PM; Harris AL; Belvin M; Friedman LS; Koeppen H; Hoeflich KP
Oncotarget; 2011 Jun; 2(6):491-6. PubMed ID: 21653999
[TBL] [Abstract][Full Text] [Related]
22. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.
Arias-Romero LE; Villamar-Cruz O; Pacheco A; Kosoff R; Huang M; Muthuswamy SK; Chernoff J
Oncogene; 2010 Oct; 29(43):5839-49. PubMed ID: 20711231
[TBL] [Abstract][Full Text] [Related]
23. p21-activated kinase 1 regulates microtubule dynamics by phosphorylating tubulin cofactor B.
Vadlamudi RK; Barnes CJ; Rayala S; Li F; Balasenthil S; Marcus S; Goodson HV; Sahin AA; Kumar R
Mol Cell Biol; 2005 May; 25(9):3726-36. PubMed ID: 15831477
[TBL] [Abstract][Full Text] [Related]
24. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
[TBL] [Abstract][Full Text] [Related]
25. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.
Ong CC; Jubb AM; Jakubiak D; Zhou W; Rudolph J; Haverty PM; Kowanetz M; Yan Y; Tremayne J; Lisle R; Harris AL; Friedman LS; Belvin M; Middleton MR; Blackwood EM; Koeppen H; Hoeflich KP
J Natl Cancer Inst; 2013 May; 105(9):606-7. PubMed ID: 23535073
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel tetrahydrothieno [2,3-c]pyridine substitued benzoyl thiourea derivatives as PAK1 inhibitors in triple negative breast cancer.
Yao D; Huang J; Wang J; He Z; Zhang J
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1524-1538. PubMed ID: 32752894
[TBL] [Abstract][Full Text] [Related]
27. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells.
Gonzalez N; Cardama GA; Comin MJ; Segatori VI; Pifano M; Alonso DF; Gomez DE; Menna PL
Cell Signal; 2017 Jan; 30():154-161. PubMed ID: 27939839
[TBL] [Abstract][Full Text] [Related]
29. Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.
McCarty SK; Saji M; Zhang X; Jarjoura D; Fusco A; Vasko VV; Ringel MD
Endocr Relat Cancer; 2010 Dec; 17(4):989-99. PubMed ID: 20817787
[TBL] [Abstract][Full Text] [Related]
30. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
31. Bioinformatics exploration of PAK1 (P21-activated kinase-1) revealed potential network gene elements in breast invasive carcinoma.
Yellapu NK; Pulaganti M; Pakala SB
J Biomol Struct Dyn; 2017 Aug; 35(10):2269-2279. PubMed ID: 27456030
[TBL] [Abstract][Full Text] [Related]
32. Centchroman prevents metastatic colonization of breast cancer cells and disrupts angiogenesis via inhibition of RAC1/PAK1/β-catenin signaling axis.
Khan S; Shukla S; Farhan M; Sinha S; Lakra AD; Penta D; Kannan A; Meeran SM
Life Sci; 2020 Sep; 256():117976. PubMed ID: 32561397
[TBL] [Abstract][Full Text] [Related]
33. Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.
Semenova G; Stepanova DS; Dubyk C; Handorf E; Deyev SM; Lazar AJ; Chernoff J
Oncogene; 2017 Sep; 36(38):5421-5431. PubMed ID: 28534510
[TBL] [Abstract][Full Text] [Related]
34. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
[TBL] [Abstract][Full Text] [Related]
35. p21-Activated kinase 1 (PAK1) in aging and longevity: An overview.
Amirthalingam M; Palanisamy S; Tawata S
Ageing Res Rev; 2021 Nov; 71():101443. PubMed ID: 34390849
[TBL] [Abstract][Full Text] [Related]
36. Integrated analysis of breast cancer cell lines reveals unique signaling pathways.
Heiser LM; Wang NJ; Talcott CL; Laderoute KR; Knapp M; Guan Y; Hu Z; Ziyad S; Weber BL; Laquerre S; Jackson JR; Wooster RF; Kuo WL; Gray JW; Spellman PT
Genome Biol; 2009; 10(3):R31. PubMed ID: 19317917
[TBL] [Abstract][Full Text] [Related]
37. Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells.
Arias-Romero LE; Villamar-Cruz O; Huang M; Hoeflich KP; Chernoff J
Cancer Res; 2013 Jun; 73(12):3671-82. PubMed ID: 23576562
[TBL] [Abstract][Full Text] [Related]
38. Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine.
Rathinasamy K; Jindal B; Asthana J; Singh P; Balaji PV; Panda D
BMC Cancer; 2010 May; 10():213. PubMed ID: 20482847
[TBL] [Abstract][Full Text] [Related]
39. Kinase shRNA screening reveals that TAOK3 enhances microtubule-targeted drug resistance of breast cancer cells via the NF-κB signaling pathway.
Lai TC; Fang CY; Jan YH; Hsieh HL; Yang YF; Liu CY; Chang PM; Hsiao M
Cell Commun Signal; 2020 Oct; 18(1):164. PubMed ID: 33087151
[TBL] [Abstract][Full Text] [Related]
40. Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL.
Siekmann IK; Dierck K; Prall S; Klokow M; Strauss J; Buhs S; Wrzeszcz A; Bockmayr M; Beck F; Trochimiuk M; Gottschling K; Martens V; Khosh-Naucke M; Gerull H; Müller J; Behrmann L; Blohm M; Zahedi RP; Jeremias I; Sickmann A; Nollau P; Horstmann MA
Blood Adv; 2018 Oct; 2(19):2554-2567. PubMed ID: 30301811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
